Welcome to our dedicated page for Bionexus Gene La SEC filings (Ticker: BGLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.
The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.
BioNexus Gene Lab Corp. highlighted its role in the 2026 China–Malaysia Economic Cooperation Outlook Forum, where CEO Sam Tan advocated moving Malaysia–China biotechnology ties beyond simple trade and toward co-development, clinical validation, and regional commercialization.
The company described a Malaysia-based ASEAN “execution hub” model using examples such as Fidelion Diagnostics and the VitaGuard™ MRD platform, linking China-origin biotechnology with international commercialization vehicles, clinical validation, and regulatory discipline. BioNexus emphasized precision diagnostics, liquid biopsy, minimal residual disease monitoring, and AI-assisted healthcare, and outlined collaboration pillars including accelerated validation of China-origin precision oncology tools, infrastructure for scalable labs, and AI-integrated healthcare that respects regional data sovereignty and privacy.
BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as Chief Commercial Officer of its affiliate Fidelion Diagnostics in connection with the Fidelion transaction. Fidelion is the international commercialization and intellectual property vehicle for the VitaGuard™ minimal residual disease liquid biopsy platform developed by Tongshu Gene.
Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships to drive adoption of advanced oncology diagnostic technologies. BioNexus holds exclusive rights to commercialize VitaGuard™ across Southeast Asia through a licensing arrangement with Fidelion, supporting its strategy to expand access to precision oncology diagnostics in the region.
BioNexus Gene Lab Corp. announced it has completed a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., and appointed Matthew L. Barsing as Chairman alongside BioNexus CFO Angeline Chong as director on Chemrex’s streamlined two-member board.
The company has centralized financial supervision and strengthened capital expenditure review and reporting protocols at Chemrex to align more closely with parent-level governance standards. A previously approved staged capital allocation framework supports potential expansion initiatives, while Chemrex’s strategic options, including biotechnology and advanced manufacturing directions, remain under evaluation with no definitive commitments yet.
BioNexus Gene Lab Corp. reported that it has formally begun the 2026 regional deployment phase of its VitaGuard™ Minimal Residual Disease (MRD) platform. This marks a shift from development-stage technology to operational deployment focused on Southeast Asia.
The company plans to integrate VitaGuard™ into routine oncology workflows at select regional medical hubs during 2026. It expects this phase to support broader commercialization, expand access to longitudinal cancer monitoring, and generate high-frequency molecular data for future AI-assisted oncology initiatives.
The update also notes that by the end of 2025 the company advanced global patent filings, set up its international commercialization structure, pursued recruitment, and planned Southeast Asia market entry with a regional diagnostics partner. Fidelion Diagnostics Pte. Ltd. will serve as the international intellectual property and commercialization vehicle outside Greater China.
BioNexus Gene Lab Corp. entered into an Equity Distribution Agreement with Maxim Group LLC to establish an at-the-market program under which the Company may offer and sell up to $20,000,000 of common stock, from time to time, through the agent.
Sales, if any, may be made on The Nasdaq Capital Market or otherwise at prevailing, related, or negotiated prices. The Company is not obligated to sell shares, and the agent is not required to purchase shares. No sales will occur unless the Company’s shelf Registration Statement on Form S-3 (File No. 333-291379) is declared effective and an applicable prospectus supplement is filed.
The agreement includes customary representations, covenants, indemnification, and termination rights. The Company also announced the ATM program via a press release furnished as an exhibit.
BioNexus Gene Lab Corp. (BGLC) entered a definitive share subscription and shareholders’ agreement with Fidelion Diagnostics to form a strategic alliance around the VitaGuard MRD platform. Upon completion, BGLC will subscribe for new Fidelion shares to hold at least 15.0% of Fidelion’s enlarged capital, and will issue restricted shares representing 19.9% of BGLC’s outstanding common stock (pre-issuance) to Fidelion as consideration.
Closing is subject to specified conditions precedent, including an exclusive Southeast Asia IP license between BGLC and Fidelion and customary consents. Governance terms allow BGLC to appoint two directors to Fidelion’s board (one Singapore resident), with reserved matters requiring enhanced approvals. Transfer restrictions, pre-emptive and over‑subscription rights, and SIAC arbitration are included.
Related‑person disclosure: as of November 11, 2025, BGLC’s CEO Su‑Leng Tan Lee beneficially owns approximately 4.1% of Fidelion and is expected to serve as Fidelion’s initial CEO; independent and disinterested directors approved the transactions, and he abstained. The BGLC share issuance will be conducted offshore under Regulation S.
BioNexus Gene Lab Corp. filed a shelf registration to offer up to $100,000,000 of securities (common stock, preferred stock, warrants, rights and units) from time to time, with terms to be set in future supplements. The filing also includes a sales agreement prospectus for an at‑the‑market program to sell up to $3,557,000 of common stock through Maxim Group LLC as exclusive sales agent.
Under the ATM, shares may be sold at prevailing market prices, and BioNexus will pay Maxim a 2.5% commission on gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes. As of this prospectus, the aggregate market value of common stock held by non‑affiliates was $10,779,582, based on 1,796,597 shares and a $6.00 per‑share price used for SEC eligibility. Pursuant to General Instruction I.B.6, while public float is under $75 million, sales off the shelf are limited to no more than one‑third of public float in any 12‑month period.
BioNexus’s common stock trades on Nasdaq as BGLC. The company is an emerging growth and smaller reporting company and may use scaled disclosures.